KKR-Led Investor Group Makes Follow-on Investment in Sylvan

January 22, 2026

KKR has completed an additional investment in Sylvan, a global mushroom spawn and fungal biotechnology company, with participation from TPG NewQuest, Ping'An Capital, China Post Insurance, Schroders Capital, Tsao Pao Chee and a follow-on from Novo Holdings. The funding will support Sylvan’s expansion—increasing production capacity, strengthening R&D, developing new product categories and deeper growth across Asian markets—while KKR remains the company’s majority investor.

Buyers
KKR, TPG NewQuest, Ping'An Capital, China Post Insurance, Schroders Capital, Tsao Pao Chee, Novo Holdings
Targets
Sylvan
Industry
Biotechnology
Location
Pennsylvania, United States
Transaction Type
Growth capital

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.